Abstract：
The objective of our study was to use quantum dots for the purpose of seeing and detecting C-C motif chemokine ligand 5 (CCL5) inside the tissue of sentinel lymph nodes (SLN) and primary tumors. This endeavor aimed to enhance the accuracy of predicting the condition of non-sentinel lymph nodes and provide valuable insights for making informed treatment choices. We analyzed breast cancer patients who underwent sentinel lymph node biopsy followed by axillary lymph node removal due to one or two positive sentinel lymph nodes at the Second People\'s Hospital of Wuhu, China, between August 2018 and July 2022. Quantum dot technology was employed to visualize and determine CCL5 in the tissue samples from 84 patients. Out of a group diagnosed with breast cancer, 208 underwent sentinel lymph node biopsy. From this pool, 84 tested positive and subsequently underwent axillary lymph node removal. The presence of distinct orange-red fluorescence, linked to quantum dots, was evident in the cellular components of both primary tumors and positive sentinel lymph node tissues. We found a significant relationship between higher levels of SLNCCL5 and advanced tumor growth (P < 0.05). To understand the predictive value of SLN CCL5 related to non-sentinel lymph node status, we utilized the receiver operating characteristic (ROC) method. The area under the curve (AUC) calculated was 0.745 with a cutoff point of 23.285. Multivariate logistic regression was used to understand the effect of tumor dimensions and SLNCCL5 levels on non-sentinel lymph node status in specific patients. Both the size of the tumor and SLNCCL5 levels were found to have a significant impact (P < 0.05). Data suggested that the presence of positive SLNCCL5 might serve as an assessment parameter for anticipating the condition of non-SLN in cases of breast cancer involving T1 or T2 tumors with one or two positive sentinel lymph nodes.
摘要：
我们研究的目的是使用量子点观察和检测前哨淋巴结（SLN）和原发性肿瘤组织内的C-C基序趋化因子配体5（CCL5）。这项努力旨在提高预测非前哨淋巴结状况的准确性，并为做出明智的治疗选择提供有价值的见解。我们分析了在芜湖市第二人民医院接受前哨淋巴结活检，然后由于一个或两个前哨淋巴结阳性而切除腋窝淋巴结的乳腺癌患者，中国,2018年8月至2022年7月。采用量子点技术来可视化和确定来自84名患者的组织样品中的CCL5。在被诊断患有乳腺癌的人群中，208例前哨淋巴结活检。从这个游泳池里，84检测为阳性，随后进行了腋窝淋巴结切除。明显的橙红色荧光的存在，连接到量子点，在原发性肿瘤和阳性前哨淋巴结组织的细胞成分中都很明显。我们发现较高水平的SLNCCL5与晚期肿瘤生长之间存在显着关系（P<0.05）。了解SLNCCL5与非前哨淋巴结状态相关的预测价值,我们使用了接收机工作特性(ROC)方法。计算的曲线下面积(AUC)为0.745,截止点为23.285。多因素logistic回归分析肿瘤大小和SLNCCL5水平对特定患者非前哨淋巴结状态的影响。发现肿瘤大小和SLNCCL5水平均具有显著影响(P<0.05)。数据表明，阳性SLNCCL5的存在可能作为评估参数，用于在涉及T1或T2肿瘤的乳腺癌患者中预测非SLN的状况具有一个或两个阳性前哨淋巴结。
